News

Eirion Therapeutics Announces Strategic Agreement with HTL Biotechnology

Sep 08, 2021, 09:00 ET Eirion Therapeutics Announces Strategic Agreement for HTL Biotechnology to Become Eirion’s Exclusive Botulinum API Manufacturer WOBURN, Mass. and JAVENÉ, France, Sept. 8, 2021 /PRNewswire/ Today, Eirion Therapeutics, Inc., an aesthetic dermatology company headquartered in Woburn, Massachusetts, announced that HTL Biotechnology, the worldwide leader in biotechnology solutions using hyaluronic acid and […]

Eirion Therapeutics Announces Strategic Agreement with HTL Biotechnology Read More »

Sight Sciences to Participate in the Morgan Stanley Global Healthcare Conference

MENLO PARK, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address the underlying causes of the world’s most prevalent eye diseases, today announced plans to participate in the upcoming virtual Morgan Stanley Global Healthcare Conference. Sight Sciences’ management

Sight Sciences to Participate in the Morgan Stanley Global Healthcare Conference Read More »

Sight Sciences Announces Publication of Favorable Two-Year Outcomes of Standalone Use of the OMNI® Surgical System in Mild to Moderate Open-Angle Glaucoma

MENLO PARK, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address the underlying causes of the world’s most prevalent eye diseases, today announced publication in Clinical Ophthalmology of favorable 24-month outcomes from a single center open-label study of

Sight Sciences Announces Publication of Favorable Two-Year Outcomes of Standalone Use of the OMNI® Surgical System in Mild to Moderate Open-Angle Glaucoma Read More »

Sight Sciences Reports Second Quarter 2021 Financial Results

MENLO PARK, Calif., August 12, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today reported financial results for the quarter ended June 30, 2021. Recent Business Highlights• Generated second quarter 2021 total revenue of $12.5

Sight Sciences Reports Second Quarter 2021 Financial Results Read More »

Koya Medical Secures First Reimbursement Codes for Dayspring, for Lymphedema and Publishes First Clinical Study Results

CMS issues new HCPCS codes for Dayspring, a novel wearable active compression treatment for lymphedema and venous diseases.   Lymphatic Research and Biology peer-reviewed journal publishes open-label controlled study evaluating efficacy of Dayspring.  OAKLAND, Calif., August 10, 2021 – Koya Medical, a healthcare company focused on developing breakthrough treatments for lymphedema and venous diseases, announced today

Koya Medical Secures First Reimbursement Codes for Dayspring, for Lymphedema and Publishes First Clinical Study Results Read More »

Empirical Spine Closes $10 Million Series B Financing — Empirical Spine

SAN CARLOS, Calif., June 2, 2021 /PRNewswire/ — Empirical Spine, Inc., maker of the LimiFlex Paraspinous Tension Band, today announced the closing of a Series B financing of $10 million. SHD (Scientific Health Development) led the round, with additional investment from GP&G (Green Park & Golf) and other syndicate members. The funds will be used

Empirical Spine Closes $10 Million Series B Financing — Empirical Spine Read More »

New Indication for Lymphedema in Lower Extremities

Dayspring compression therapy system is now FDA cleared for treatment of lymphedema and venous diseases in both upper and lower extremities Koya Medical strengthens leadership team with appointments of three industry veterans to support commercial expansion OAKLAND, Calif., May 26, 2021 — Koya Medical, a healthcare company focused on developing breakthrough treatments for lymphedema and

New Indication for Lymphedema in Lower Extremities Read More »

Procyrion Announces Successful First-in-Human Cases in Cardiorenal Syndrome (CRS) Patients with Aortix™ Percutaneous Mechanical Circulatory Support Device

Pilot CRS Study to Evaluate Performance of Novel Aortix device in Australia and the U.S. HOUSTON, TX – MAY 25, 2021 – Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today successful treatment of the first patients in the company’s pilot trial to evaluate the

Procyrion Announces Successful First-in-Human Cases in Cardiorenal Syndrome (CRS) Patients with Aortix™ Percutaneous Mechanical Circulatory Support Device Read More »

Koya Medical Presents at Oppenheimer MedTech

OAKLAND, Calif., May 20, 2021 — Koya Medical, a healthcare company focused on developing breakthrough treatments for lymphedema and venous diseases, will present at the Oppenheimer MedTech, Tools & Diagnostics Summit on Wednesday, May 26, 2021. Koya Founder, CEO and President Andy Doraiswamy, Ph.D., will provide an overview of Koya’s recent business milestones and developments

Koya Medical Presents at Oppenheimer MedTech Read More »